QuantuMDx/GIS Collaborate To Develop Asia-Specific Assays For Use With Q-POC

Agency for Science, Technology and Research's Genome Institute of Singapore (GIS) has signed an agreement with QuantuMDx (QMDx), under which, QMDx' wholly owned Singapore-based subsidiary, QMDx Asia, and GIS will develop Asia-specific point-of-care (PoC) genetic tests for use with QMDx' Q-POC hand held PoC device. QMDx will commercialise the tests. The first assay from the development pipeline will direct treatment of East Asian patients with kinase-driven cancers, such as chronic myeloid leukaemia and EGFr-mutated non-small lung cancer.

QMDx' hand-held, PoC, sample-to-result diagnostic device, Q-POC, will be used to rapidly test patients, in a cancer clinic or post-surgery, for the presence of a BIM deletion polymorphism genetic mutation which GIS has shown causes a patient's malignancy to be unresponsive to the standard tyrosine kinase inhibitors treatment regime. Instead, the treatment can be personalised and made more effective by switching treatment to other chemotherapeutic agents. Q-POC, currently at prototype stage, utilises novel sample preparation, extraction, amplification and a nanowire biosensor to detect DNA sequences of interest in under 15 minutes, from sample to result.


Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.